Amyris (NASDAQ:AMRS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday.
According to Zacks, “Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA. “
Several other research analysts have also weighed in on AMRS. HC Wainwright set a $15.00 target price on Amyris and gave the stock a “buy” rating in a report on Wednesday, November 29th. ValuEngine lowered Amyris from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. B. Riley assumed coverage on Amyris in a report on Thursday, January 25th. They set a “buy” rating and a $8.00 target price on the stock. Finally, Cowen reiterated a “hold” rating and set a $4.00 target price on shares of Amyris in a report on Wednesday, November 29th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $7.69.
Amyris (NASDAQ:AMRS) last announced its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.04). The company had revenue of $24.20 million during the quarter, compared to analyst estimates of $36.30 million. During the same period in the previous year, the business posted ($0.07) earnings per share. The firm’s revenue for the quarter was down 8.8% compared to the same quarter last year. research analysts predict that Amyris will post -3.42 earnings per share for the current fiscal year.
In other Amyris news, insider John Melo sold 10,776 shares of Amyris stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $4.68, for a total transaction of $50,431.68. Following the transaction, the insider now directly owns 83,172 shares in the company, valued at $389,244.96. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 11.30% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp lifted its holdings in shares of Amyris by 16.3% in the second quarter. Bank of New York Mellon Corp now owns 32,768 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 4,603 shares in the last quarter. Carl Domino Inc bought a new stake in shares of Amyris in the third quarter valued at about $182,000. Creative Planning bought a new stake in shares of Amyris in the fourth quarter valued at about $188,000. KBC Group NV lifted its holdings in shares of Amyris by 228.4% in the third quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 41,834 shares in the last quarter. Finally, Tanaka Capital Management Inc. lifted its holdings in shares of Amyris by 72.0% in the third quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock valued at $1,691,000 after purchasing an additional 221,295 shares in the last quarter. Institutional investors own 22.96% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/30/amyris-amrs-downgraded-by-zacks-investment-research.html.
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.